Leukotuximab - DiNonA

Drug Profile

Leukotuximab - DiNonA

Alternative Names: Anti-JL1 monoclonal antibody; ART-140; DNP-001; EGX-040; EGX-140; SSS-19

Latest Information Update: 28 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Seoul
  • Developer 3SBio; Arana Therapeutics; Asan Medical Center; DiNonA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action JL1 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia
  • No development reported Myelodysplastic syndromes

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Leukaemia and Myelodysplastic syndromes (Second-line therapy or greater, In adults, In the elderly) in South Korea (IV)
  • 12 May 2016 Preclinical trials in Leukaemia in China (Parenteral)
  • 13 Aug 2014 No development reported - Preclinical for Leukaemia in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top